Scinai Immunotherapeutics Raises $2.61M to Expand CDMO Platform and Advance Pipeline
Scinai Immunotherapeutics announced a $2.61 million private placement and warrant inducement, with proceeds supporting its CDMO expansion and immunotherapy pipeline.
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has entered into a securities purchase agreement with institutional and accredited investors to sell 5,208,333 American Depositary Shares (ADSs) at $0.48 per ADS, along with accompanying Series A and Series B warrants, the company announced today. Separately, the company executed a warrant inducement agreement with an existing investor. The combined transactions are expected to generate approximately $2.61 million in gross proceeds, with closing anticipated on or about April 27, 2026, subject to customary conditions.
The funding comes at a pivotal time for Scinai, which is looking to scale its contract development and manufacturing organization (CDMO) business. The company said proceeds will support expansion of its CDMO platform, advancement of customer programs, and continued investment in its immunotherapy pipeline. This capital injection could help Scinai carve out a larger footprint in the growing CDMO market, where demand for specialized biopharmaceutical manufacturing services remains high.
Scinai's pipeline includes therapeutic candidates licensed from the Max Planck Society and PinCell S.r.l., targeting innovative immunology therapies. The company also operates Scinai Biopharma Services Ltd., a CDMO providing development and manufacturing services to other biotechnology and pharmaceutical firms. By strengthening its CDMO capabilities, Scinai can potentially generate recurring revenue while advancing its own drug candidates.
The warrant inducement agreement and private placement structure indicate that the company is leveraging existing investor relationships to raise capital efficiently. For the existing investor exercising warrants, this could signal confidence in Scinai's strategic direction. However, the issuance of new shares and warrants dilutes current shareholders, a common trade-off for biotech companies needing capital to fund operations and growth.
For investors, the key takeaway is Scinai's dual focus: using its CDMO to generate near-term cash flow while investing in its pipeline for long-term value. The company's ability to execute on both fronts will be critical. The market will be watching how quickly Scinai can convert these funds into tangible progress on customer contracts and clinical milestones.
Full details of the transaction are available in the press release at https://ibn.fm/6Vw4O. For the latest news on Scinai, visit the company's newsroom at https://ibn.fm/SCNI.